NORTHAMPTON, MASSACHUSETTS,- Achieve TMS East, Massachusett’s leading provider of Deep Transcranial Magnetic Stimulation (dTMS), is pleased to announce that Brainsway, which manufacturers dTMS technologies for the treatment of brain disorders, has received approval from the US Food and Drug Administration (FDA) for its non-invasive device in the treatment of obsessive-compulsive disorder (OCD).  FDA approval of deep TMS therapy for the treatment of OCD represents a significant advance in the treatment of this disease.

OCD is a mental illness in which individuals can have either obsessive thoughts and urges or compulsive, repetitive behaviors, such as repetitive hand washing.  Some patients suffer with both obsessions and compulsions.

Over 2 million adults are diagnosed with obsessive-compulsive disorder (OCD) each year and approximately 50% of OCD patients are resistant to current first line treatment methods, including medications. Deep TMS therapy is a non-invasive treatment with little to no side effects, making it a game changer for those suffering from treatment-resistant OCD and depression.

“Brainsway’s OCD certification marks a historic milestone in the treatment of this disorder. This is a new treatment option for patients seeking a meaningful and life-changing OCD solution,” said Dr. Joseph Zohar, a professor of psychiatry at the Sackler School of Medicine at Tel Aviv University and chairman of the International Organization for Compulsive Interference Disorder (ICOCS) and lead author of the OCD trial (Nocamels, 2018).

Carlos Peña, Ph.D., M.S., director of the Division of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health, stated “with today’s marketing authorization, patients with OCD who have not responded to traditional treatments now have another option” (Leonard, 2018).

“Achieve TMS East has had outstanding results treating patients with major depression in 11 locations throughout the state and we now are excited to extend our services to those suffering with OCD with this new, cutting-edge technology,” states Dr. John Zebrun, Senior Medical Officer at Achieve TMS East.   Margie Pierce, Director of Operations, adds “that the same high standards of patient care will be offered for OCD as have been previously available for Depression – all in a relaxed, comfortable environment with extended appointment hours for patient convenience. “

For more information, please call Anita Taylor at 413-265-3844 or e-mail


Brainsway Device For Non-Invasive Treatment Of OCD Gets FDA Approval | News Brief. (2018, August 1). Retrieved from

Leonard, K. (2018, August 17). FDA approves magnetic stimulation to treat OCD. Retrieved from

Call Now Button